Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director | July 23, 2025 | July 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date July 23, 2025 · Filed July 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2035-07-22 | Direct | 17,500 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Grant · Acquired 17,500 · Balance 17,500 F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2025 Filed Jul 23, 2025 23:42 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-25-098046 · ownership.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-07-22 F1 · derivative.exercise_date: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| December 02, 2024 Filed Dec 6, 2024 21:41 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-134167 · ownership.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:09 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-099840 · ownership.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-08-19 F1 · derivative.exercise_date: This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 00:33 UTC Amendment | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 1,133,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-22-012858 · doc4a.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,000 Underlying: Common Stock · 1,133,000 shares Expires 2032-03-29 F1 · date: This amendment is being filed to correct the date of grant and the exercise price for the stock option reported on a Form 4 filed by the reporting person on March 24, 2022. This option became effective on March 30, 2022. F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal monthly installments through March 30, 2026. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 23:44 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 1,133,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000899243-22-012148 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,000 Underlying: Common Stock · 1,133,000 shares Expires 2032-03-21 F1 · derivative.exercise_date: This option was granted on March 22, 2022. The shares underlying the option are scheduled to vest in equal monthly installments through March 22, 2026. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:56 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,440,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024532 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,440,000 Underlying: Common Stock · 2,440,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest as to 25% of the shares on June 15, 2022 and thereafter in equal monthly installments through June 15, 2025. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:31 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-20-002805 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: This option was granted on January 31, 2020. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 31, 2020. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 22:41 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-19-010813 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 21:47 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 232,914 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0000899243-18-024025 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,914 Underlying: Common Stock · 232,914 shares Expires 2028-09-05 F1 · derivative.exercise_date: This option was granted on September 6, 2018. The shares underlying the option are scheduled to vest in equal monthly installments over four years from September 6, 2018. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 1,000 | $5.61 | $5,610.00 |
DisclosureSEC source: 0000899243-18-015782 · doc4.xml · nonDerivative · entry 1 Aivado Manuel · CIK 0001709603 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 22:36 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 57,388 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019222 · doc4.xml · derivative · entry 1 Aivado Manuel · CIK 0001709603 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,388 Underlying: Common Stock · 57,388 shares Expires 2027-07-24 F1 · derivative.exercise_date: This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from July 25, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.